Effect of institutional differences on study of surfactant in two centers.
Etches
P C
PC
Peliowski
A
A
Finer
N N
NN
Tierney
A J
AJ
D001997:Bronchopulmonary Dysplasia / Q000188:drug therapy / Q000401:mortality*; D004338:Drug Combinations; D005233:Fatty Alcohols / Q000627:therapeutic use; D006761:Hospitals; D006801:Humans; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D015337:Multicenter Studies as Topic; D010767:Phosphorylcholine; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011663:Pulmonary Surfactants / Q000627:therapeutic use; D014481:United States
D004338:Drug Combinations; D005233:Fatty Alcohols; D011663:Pulmonary Surfactants; D010767:Phosphorylcholine; D011092:Polyethylene Glycols; C047049:dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination